GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00450106 | Prostate | BPH | actin nucleation | 22/3107 | 52/18723 | 1.05e-05 | 1.44e-04 | 22 |
GO:001081118 | Prostate | BPH | positive regulation of cell-substrate adhesion | 40/3107 | 123/18723 | 1.05e-05 | 1.44e-04 | 40 |
GO:001943910 | Prostate | BPH | aromatic compound catabolic process | 113/3107 | 467/18723 | 1.30e-05 | 1.72e-04 | 113 |
GO:005149410 | Prostate | BPH | negative regulation of cytoskeleton organization | 49/3107 | 163/18723 | 1.32e-05 | 1.74e-04 | 49 |
GO:00605377 | Prostate | BPH | muscle tissue development | 100/3107 | 403/18723 | 1.35e-05 | 1.76e-04 | 100 |
GO:00507678 | Prostate | BPH | regulation of neurogenesis | 92/3107 | 364/18723 | 1.36e-05 | 1.78e-04 | 92 |
GO:002240716 | Prostate | BPH | regulation of cell-cell adhesion | 109/3107 | 448/18723 | 1.43e-05 | 1.85e-04 | 109 |
GO:19028063 | Prostate | BPH | regulation of cell cycle G1/S phase transition | 50/3107 | 168/18723 | 1.47e-05 | 1.89e-04 | 50 |
GO:00714787 | Prostate | BPH | cellular response to radiation | 54/3107 | 186/18723 | 1.50e-05 | 1.92e-04 | 54 |
GO:00063259 | Prostate | BPH | chromatin organization | 101/3107 | 409/18723 | 1.52e-05 | 1.94e-04 | 101 |
GO:00109705 | Prostate | BPH | transport along microtubule | 47/3107 | 155/18723 | 1.53e-05 | 1.95e-04 | 47 |
GO:20000454 | Prostate | BPH | regulation of G1/S transition of mitotic cell cycle | 44/3107 | 142/18723 | 1.55e-05 | 1.96e-04 | 44 |
GO:000926010 | Prostate | BPH | ribonucleotide biosynthetic process | 53/3107 | 182/18723 | 1.63e-05 | 2.05e-04 | 53 |
GO:000662616 | Prostate | BPH | protein targeting to mitochondrion | 34/3107 | 100/18723 | 1.64e-05 | 2.05e-04 | 34 |
GO:190136110 | Prostate | BPH | organic cyclic compound catabolic process | 118/3107 | 495/18723 | 1.75e-05 | 2.17e-04 | 118 |
GO:00457878 | Prostate | BPH | positive regulation of cell cycle | 81/3107 | 313/18723 | 1.76e-05 | 2.18e-04 | 81 |
GO:00430879 | Prostate | BPH | regulation of GTPase activity | 88/3107 | 348/18723 | 2.04e-05 | 2.49e-04 | 88 |
GO:000675316 | Prostate | BPH | nucleoside phosphate metabolic process | 118/3107 | 497/18723 | 2.13e-05 | 2.58e-04 | 118 |
GO:00164855 | Prostate | BPH | protein processing | 62/3107 | 225/18723 | 2.22e-05 | 2.67e-04 | 62 |
GO:005134616 | Prostate | BPH | negative regulation of hydrolase activity | 94/3107 | 379/18723 | 2.46e-05 | 2.94e-04 | 94 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0002014 | Esophagus | ESCC | Citrate cycle (TCA cycle) | 27/4205 | 30/8465 | 3.48e-06 | 1.94e-05 | 9.95e-06 | 27 |
hsa0120023 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0123023 | Esophagus | ESCC | Biosynthesis of amino acids | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
hsa0062023 | Esophagus | ESCC | Pyruvate metabolism | 32/4205 | 47/8465 | 8.11e-03 | 1.94e-02 | 9.94e-03 | 32 |
hsa0002015 | Esophagus | ESCC | Citrate cycle (TCA cycle) | 27/4205 | 30/8465 | 3.48e-06 | 1.94e-05 | 9.95e-06 | 27 |
hsa0120033 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0123033 | Esophagus | ESCC | Biosynthesis of amino acids | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
hsa0062033 | Esophagus | ESCC | Pyruvate metabolism | 32/4205 | 47/8465 | 8.11e-03 | 1.94e-02 | 9.94e-03 | 32 |
hsa0120010 | Liver | NAFLD | Carbon metabolism | 26/1043 | 115/8465 | 1.39e-03 | 1.71e-02 | 1.38e-02 | 26 |
hsa0120011 | Liver | NAFLD | Carbon metabolism | 26/1043 | 115/8465 | 1.39e-03 | 1.71e-02 | 1.38e-02 | 26 |
hsa0120021 | Liver | Cirrhotic | Carbon metabolism | 64/2530 | 115/8465 | 6.37e-09 | 1.18e-07 | 7.26e-08 | 64 |
hsa006208 | Liver | Cirrhotic | Pyruvate metabolism | 29/2530 | 47/8465 | 5.90e-06 | 5.95e-05 | 3.67e-05 | 29 |
hsa0002010 | Liver | Cirrhotic | Citrate cycle (TCA cycle) | 21/2530 | 30/8465 | 6.56e-06 | 6.24e-05 | 3.84e-05 | 21 |
hsa012304 | Liver | Cirrhotic | Biosynthesis of amino acids | 35/2530 | 75/8465 | 1.54e-03 | 7.83e-03 | 4.83e-03 | 35 |
hsa0120031 | Liver | Cirrhotic | Carbon metabolism | 64/2530 | 115/8465 | 6.37e-09 | 1.18e-07 | 7.26e-08 | 64 |
hsa0062011 | Liver | Cirrhotic | Pyruvate metabolism | 29/2530 | 47/8465 | 5.90e-06 | 5.95e-05 | 3.67e-05 | 29 |
hsa0002011 | Liver | Cirrhotic | Citrate cycle (TCA cycle) | 21/2530 | 30/8465 | 6.56e-06 | 6.24e-05 | 3.84e-05 | 21 |
hsa0123011 | Liver | Cirrhotic | Biosynthesis of amino acids | 35/2530 | 75/8465 | 1.54e-03 | 7.83e-03 | 4.83e-03 | 35 |
hsa0120041 | Liver | HCC | Carbon metabolism | 89/4020 | 115/8465 | 3.92e-11 | 6.56e-10 | 3.65e-10 | 89 |
hsa0002021 | Liver | HCC | Citrate cycle (TCA cycle) | 28/4020 | 30/8465 | 1.08e-07 | 1.44e-06 | 8.02e-07 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PC | SNV | Missense_Mutation | novel | c.1378N>A | p.Ala460Thr | p.A460T | P11498 | protein_coding | deleterious(0.01) | benign(0.108) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | novel | c.1726N>G | p.Ser576Ala | p.S576A | P11498 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
PC | SNV | Missense_Mutation | | c.619N>C | p.Val207Leu | p.V207L | P11498 | protein_coding | deleterious(0.01) | possibly_damaging(0.822) | TCGA-B6-A0I6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PC | SNV | Missense_Mutation | | c.584C>T | p.Ala195Val | p.A195V | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
PC | SNV | Missense_Mutation | rs119103242 | c.1748N>A | p.Arg583His | p.R583H | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | | c.1217G>A | p.Arg406His | p.R406H | P11498 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-C8-A138-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | | c.730N>T | p.His244Tyr | p.H244Y | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | | c.1848N>A | p.Met616Ile | p.M616I | P11498 | protein_coding | deleterious(0.01) | benign(0.059) | TCGA-EW-A1PD-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Chemotherapy | docetaxel | SD |
PC | SNV | Missense_Mutation | novel | c.151N>A | p.Arg51Ser | p.R51S | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A6SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | aromatase | SD |
PC | SNV | Missense_Mutation | | c.2395N>A | p.Asp799Asn | p.D799N | P11498 | protein_coding | tolerated(0.18) | probably_damaging(0.967) | TCGA-DS-A0VK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |